JP2020516277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516277A5 JP2020516277A5 JP2019555574A JP2019555574A JP2020516277A5 JP 2020516277 A5 JP2020516277 A5 JP 2020516277A5 JP 2019555574 A JP2019555574 A JP 2019555574A JP 2019555574 A JP2019555574 A JP 2019555574A JP 2020516277 A5 JP2020516277 A5 JP 2020516277A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- recombinant
- seq
- deletion
- disintegrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 26
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 238000012217 deletion Methods 0.000 claims 25
- 230000037430 deletion Effects 0.000 claims 25
- 241000701161 unidentified adenovirus Species 0.000 claims 24
- 238000000034 method Methods 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 241000700605 Viruses Species 0.000 claims 11
- 108700019146 Transgenes Proteins 0.000 claims 6
- 230000000174 oncolytic effect Effects 0.000 claims 5
- 239000013592 cell lysate Substances 0.000 claims 4
- 239000012679 serum free medium Substances 0.000 claims 4
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- -1 optionally Proteins 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 claims 2
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 2
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 2
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 108700026226 TATA Box Proteins 0.000 claims 2
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000004255 ion exchange chromatography Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101710113110 B-cell receptor-associated protein 31 Proteins 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims 1
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 1
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 claims 1
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 101710139711 IkB-like protein Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 101710081123 Interleukin-27 subunit alpha Proteins 0.000 claims 1
- 101710116301 Interleukin-27 subunit beta Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102100039897 Interleukin-5 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 102000003898 interleukin-24 Human genes 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000004114 suspension culture Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023020698A JP2023053298A (ja) | 2017-04-10 | 2023-02-14 | 組み換えウイルスを産生するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483837P | 2017-04-10 | 2017-04-10 | |
| US62/483,837 | 2017-04-10 | ||
| PCT/US2018/026977 WO2018191313A1 (en) | 2017-04-10 | 2018-04-10 | Method for producing recombinant virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020698A Division JP2023053298A (ja) | 2017-04-10 | 2023-02-14 | 組み換えウイルスを産生するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516277A JP2020516277A (ja) | 2020-06-11 |
| JP2020516277A5 true JP2020516277A5 (enExample) | 2021-05-20 |
| JP7229173B2 JP7229173B2 (ja) | 2023-02-27 |
Family
ID=63792776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555574A Active JP7229173B2 (ja) | 2017-04-10 | 2018-04-10 | 組み換えウイルスを産生するための方法 |
| JP2023020698A Withdrawn JP2023053298A (ja) | 2017-04-10 | 2023-02-14 | 組み換えウイルスを産生するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020698A Withdrawn JP2023053298A (ja) | 2017-04-10 | 2023-02-14 | 組み換えウイルスを産生するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11999973B2 (enExample) |
| EP (1) | EP3610003A4 (enExample) |
| JP (2) | JP7229173B2 (enExample) |
| KR (2) | KR20240032169A (enExample) |
| CN (1) | CN111133102B (enExample) |
| AU (1) | AU2018253088B2 (enExample) |
| CA (1) | CA3059605A1 (enExample) |
| WO (1) | WO2018191313A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EP3610003A4 (en) * | 2017-04-10 | 2021-01-06 | EpicentRx, Inc. | RECOMBINANT VIRUS PRODUCTION PROCESS |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN111793595A (zh) * | 2020-07-23 | 2020-10-20 | 上海奥浦迈生物科技有限公司 | 一种hek293细胞无血清培养基 |
| EP4554559A1 (en) | 2022-07-13 | 2025-05-21 | EpicentRx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6113913A (en) * | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| WO2003039459A2 (en) | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
| US20050153419A1 (en) | 2003-12-23 | 2005-07-14 | Schering Corporation | Methods for producing cell lines stable in serum-free medium suspension culture |
| JP4301558B2 (ja) * | 2003-12-26 | 2009-07-22 | 日東電工株式会社 | 偏光板用接着剤、偏光板、その製造方法、光学フィルムおよび画像表示装置 |
| PT2403951E (pt) * | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| US20190352669A1 (en) * | 2017-01-30 | 2019-11-21 | Epicentrx, Inc. | Tumor selective tata-box and caat-box mutants |
| EP3610003A4 (en) * | 2017-04-10 | 2021-01-06 | EpicentRx, Inc. | RECOMBINANT VIRUS PRODUCTION PROCESS |
-
2018
- 2018-04-10 EP EP18785009.4A patent/EP3610003A4/en active Pending
- 2018-04-10 WO PCT/US2018/026977 patent/WO2018191313A1/en not_active Ceased
- 2018-04-10 KR KR1020247006527A patent/KR20240032169A/ko not_active Ceased
- 2018-04-10 CN CN201880038591.8A patent/CN111133102B/zh active Active
- 2018-04-10 AU AU2018253088A patent/AU2018253088B2/en active Active
- 2018-04-10 KR KR1020197033110A patent/KR102643016B1/ko active Active
- 2018-04-10 US US16/604,194 patent/US11999973B2/en active Active
- 2018-04-10 CA CA3059605A patent/CA3059605A1/en active Pending
- 2018-04-10 JP JP2019555574A patent/JP7229173B2/ja active Active
-
2023
- 2023-02-14 JP JP2023020698A patent/JP2023053298A/ja not_active Withdrawn
-
2024
- 2024-04-29 US US18/649,467 patent/US12291726B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516277A5 (enExample) | ||
| JP2022163182A5 (enExample) | ||
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| JP2019523008A5 (enExample) | ||
| Szalay et al. | Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders | |
| Günther et al. | A comparative epigenome analysis of gammaherpesviruses suggests cis-acting sequence features as critical mediators of rapid polycomb recruitment | |
| HRP20110179T1 (hr) | Kimerni adenovirusi za uporabu u liječenju raka | |
| JP2020505049A5 (enExample) | ||
| CN111133102B (zh) | 生产重组病毒的方法 | |
| CN1124040A (zh) | 病毒载体和基因治疗应用 | |
| WO2023165009A1 (zh) | 一种用于制备环状rna的载体及其应用 | |
| WO2005121343A1 (en) | Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof | |
| WO2020076820A3 (en) | Compositions and methods for preparing viral vectors | |
| CN104087613B (zh) | 基于aav‑itr的基因表达微载体及其构建方法和应用 | |
| Amado et al. | MicroRNA-181a regulates IFN-γ expression in effector CD8+ T cell differentiation | |
| Machitani et al. | Dicer functions as an antiviral system against human adenoviruses via cleavage of adenovirus-encoded noncoding RNA | |
| Sorel et al. | MicroRNAs in large herpesvirus DNA genomes: recent advances | |
| Zhang et al. | Insights into leghorn male hepatocellular cells response to fowl adenovirus serotype 4 infection by transcriptome analysis | |
| JP5645044B2 (ja) | 遺伝子発現制御機構を含む新規Ａｄベクター | |
| Gong et al. | Stable transfection into rat bone marrow mesenchymal stem cells by lentivirus-mediated NT-3 | |
| Wang et al. | Recombinant adenovirus vector-mediated functional expression of neurotropin-3 receptor (TrkC) in neural stem cells | |
| Zhu et al. | Viral miRNA targeting of bicistronic and polycistronic transcripts | |
| Machitani et al. | Development of an adenovirus vector lacking the expression of virus-associated RNAs | |
| CN101787374A (zh) | 一种基于微小rna调控可在肿瘤细胞内特异性增殖的重组腺病毒载体、其构建方法及其用途 | |
| CN116179604A (zh) | 一种降低回复突变频率的重组5型腺病毒载体及其构建方法 |